Used in cancer research to reactivate latent HIV in combination with other agents, making it a potential candidate for HIV eradication strategies. It functions as a SMARCA2 degrader, targeting specific epigenetic regulators in tumor cells, showing promise in treating certain resistant cancers. Currently under investigation in preclinical and early clinical trials for oncology and virology applications.